查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1888684

药物安全检测和药物安全软体市场规模、份额和趋势分析报告：按功能、部署、最终用途、地区和细分市场预测（2025-2033 年）

Pharmacovigilance And Drug Safety Software Market Size, Share & Trends Analysis Report By Functionality, By Deployment, By End Use, By Region, And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 190 Pages | 商品交期: 2-10个工作天内

价格

药物安全检测与药物安全软体市场摘要

2024 年全球药物安全检测与药物安全软体市场规模为 2.1096 亿美元，预计到 2033 年将达到 3.8874 亿美元。

预计从 2025 年到 2033 年，该市场将以 7.1% 的复合年增长率成长。数据可用性的提高、处理产生的数据并从中得出见解的需求、严格的报告规范和标准，以及主要企业不断增加的软体升级，都是推动该市场发展的主要因素。

Accenture的INTIENT药物警戒平台是一套用于收集和管理药物警戒资料的综合产品套件。该平台能够帮助机构识别潜在的合规性问题、新兴趋势并报告不利事件。药物不良反应（ADR）和用药错误的发生率不断上升是推动产业成长的关键因素。随着药物治疗复杂性的增加和多重用药的普遍存在，医疗保健系统面临不利事件的风险，这些事件会危及病患安全并增加住院率。 Springer Nature发表的一项研究发现，在2018年6月至2021年5月期间，5707名因急性疾病入院的连续患者中，因药物不良反应导致的急诊住院率为5.0%（95% CI 4.5-5.6%）。这些发现凸显了开发先进的药物安全检测方案的必要性，这些解决方案能够透过即时监测和自动化报告系统，有效地检测、分析和预防药物相关风险。

此外，来自欧洲药品管理局 (EMA) 和美国食品药物管理局(FDA) 等政府机构制定的安全准则所带来的日益增长的合规压力，也促使药物安全检测得到广泛应用。许多製药公司正转向将药物安全检测活动外包，以控制营运成本。製造商正逐步从完全一体化的製药公司模式转向与服务供应商建立成本分摊的合作伙伴关係。外包服务涵盖医学写作、临床试验数据收集、医学报告以及其他药物警戒服务。外包能够提高内部资源的柔软性，缩短时间，并带来更好的结果。

目录

第一章调查方法和范围

第二章执行摘要

第三章 市场变数、趋势与范围

  • 市场趋势展望
  • 市场动态
  • 商业环境分析
    • 波特五力分析
    • PESTLE分析

第四章药物安全检测和药物安全软体市场：按部署方式分類的估算和趋势分析

  • 部署仪表板
  • 按部署方式分類的市占率变化分析（2024 年和 2033 年）
  • 按部署方式分類的市场规模、预测与趋势分析（2021 年至 2033 年）
  • 本地部署
  • 一经请求

第五章药物安全检测与药物安全软体市场：功能、性别比例估算与趋势分析

  • 功能性性别仪表板
  • 按功能分類的市占率变化分析（2024 年和 2033 年）
  • 功能性别市场规模、预测与趋势分析（2021-2033）
  • 病例资料收集与管理
  • 不利事件通报与分析
  • 讯号侦测及其他安全风险评估

第六章药物安全检测和药物安全软体市场：按最终用途分類的估算和趋势分析

  • 按最终用途分類的市占率变化分析（2024 年和 2033 年）
  • 按最终用途分類的市场规模、预测和趋势分析（2021-2033 年）
  • 医疗保健公司（製药和生物技术公司）
  • CRO/BPO 或 PV服务供应商（外包时）
  • 其他的

第七章药物安全检测和药物安全软体市场：按地区分類的估算和趋势分析

  • 区域市场概览
  • 区域市场：主要结论
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 丹麦
    • 瑞典
    • 挪威
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 韩国
    • 澳洲
    • 泰国
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第八章 竞争情势

  • 参与企业概况
  • 企业市场分析/企业市场占有率分析（2024）
  • 公司分类
  • 策略规划
  • 公司简介/列表
    • Oracle（Cerner）
    • Accenture
    • IBM Corporation
    • ITClinical
    • UBC（United BioSource Corporation）
    • Ab Cube
    • Ennov
    • EXTEDO
    • Veeva Systems
    • IQVIA
    • Sarjen Systems Pvt. Ltd.
    • Flex Databases
    • Tepsivo Oy
    • ArisGlobal
    • EVERSANA
Product Code: GVR-1-68038-144-3

Pharmacovigilance And Drug Safety Software Market Summary

The global pharmacovigilance and drug safety software market size was valued at USD 210.96 million in 2024 and is projected to reach USD 388.74 million by 2033, growing at a CAGR of 7.1% from 2025 to 2033. The growing availability of data, the need to process & derive insights from the generated data, stringent reporting norms & standards, and increasing software upgrades by key companies are some of the key drivers of this market.

INTIENT Pharmacovigilance by Accenture is a comprehensive product suite that helps in the collection and management of a full spectrum of pharmacovigilance data. The platform also enables users to understand potential compliance issues and emerging trends and report on adverse events. The rising incidence of adverse drug reactions (ADRs) and medication errors is a key factor driving the growth of the industry. As drug therapies become more complex and polypharmacy increases, healthcare systems face greater risks of adverse events that compromise patient safety and increase hospitalizations. According to an article published by Springer Nature, the proportion of urgent hospitalizations caused by ADRs was reported as 5.0% (95% CI 4.5-5.6%) among 5,707 consecutive patients hospitalized for acute medical illnesses between June 2018 and May 2021. Such findings highlight the critical need for advanced pharmacovigilance solutions that can efficiently detect, analyze, and prevent drug-related risks through real-time monitoring and automated reporting systems.

Moreover, increasing pressure to follow safety guidelines set by government authorities such as the European Medicines Agency and the U.S. FDA is contributing to the growing adoption of pharmacovigilance systems. Many pharmaceutical companies are moving toward outsourcing pharmacovigilance activities to curb operational costs. Manufacturers are gradually shifting from being fully integrated pharmaceutical companies to sharing costs by collaborating with service providers. Services outsourced range from medical writing and clinical trial data collection to medical reporting and other PV services. Outsourcing helps increase internal resource flexibility, improves timelines, and results in better outcomes.

Gobal Pharmacovigilance And Drug Safety Software Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global pharmacovigilance and drug safety software market report based on deployment, functionality, end use, and regions.

  • Deployment Outlook (Revenue, USD Million, 2021 - 2033)
  • On Premise
  • On Demand
  • Functionality Outlook (Revenue, USD Million, 2021 - 2033)
  • Case data collection and management
  • Adverse event reporting and analysis
  • Signal detection and other safety risk assessment
  • End Use Outlook (Revenue, USD Million, 2021 - 2033)
  • Healthcare Companies (Pharmaceuticals & Biotechnology Companies)
  • CROs/BPOs or PV service providers when outsourced.
  • Others
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East and Africa (MEA)
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Deployment
    • 1.2.2. Functionality
    • 1.2.3. End use
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Growing drug consumption and drug development rates
      • 3.2.1.2. Increasing incidence of ADR and drug toxicity
      • 3.2.1.3. Increasing trend of outsourcing pharmacovigilance services
      • 3.2.1.4. Increasing externalization of clinical trial studies by large pharmaceutical and biopharmaceutical companies
      • 3.2.1.5. Increasing regulatory burden on manufacturers
      • 3.2.1.6. Introduction of technologically advanced software services
      • 3.2.1.7. Rising investment on R&D by healthcare companies
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. Shortage of skilled professionals
      • 3.2.2.2. Expensive technology for small and mid-sized Players
      • 3.2.2.3. Lack of Recognition
      • 3.2.2.4. Scarcity of integration standards
    • 3.2.3. Industry Opportunity Analysis
    • 3.2.4. Industry Challenge Analysis
    • 3.2.5. PV Services Pricing Models
      • 3.2.5.1. Drug Safety Budget Allocation By Activities
      • 3.2.5.2. By Development Phase
      • 3.2.5.3. By Therapeutic Area
      • 3.2.5.4. Pricing Level
        • 3.2.5.4.1.Project management
        • 3.2.5.4.2.Case processing
        • 3.2.5.4.3.ADR Reporting
        • 3.2.5.4.4.Medical writing
        • 3.2.5.4.5.Drug safety management
    • 3.2.6. Technology Overview
    • 3.2.7. Case Studies
    • 3.2.8. Inflation's Impact on the Overall PV and Drug Safety Software Market
    • 3.2.9. Market Competitive Factors and Strategies
    • 3.2.10. Healthcare Companies Using PV Services
  • 3.3. Business Environment Analysis
    • 3.3.1. Porter's Five Forces Analysis
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTLE Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Economic and Social landscape
      • 3.3.2.3. Technological landscape
      • 3.3.2.4. Environmental landscape
      • 3.3.2.5. Legal Landscape

Chapter 4. Pharmacovigilance and Drug Safety Software Market: Deployment Estimates & Trend Analysis

  • 4.1. Deployment Dashboard
  • 4.2. Deployment Market Share Movement Analysis, 2024 & 2033
  • 4.3. Market Size & Forecasts and Trend Analysis, by Deployment, 2021 to 2033 (USD Million)
  • 4.4. On-Premise
    • 4.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.5. On-Demand
    • 4.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Pharmacovigilance and Drug Safety Software Market: Functionality Estimates & Trend Analysis

  • 5.1. Functionality Dashboard
  • 5.2. Functionality Market Share Movement Analysis, 2024 & 2033
  • 5.3. Market Size & Forecasts and Trend Analysis, by Functionality, 2021 to 2033 (USD Million)
  • 5.4. Case data collection and management
    • 5.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.5. Adverse event reporting and analysis
    • 5.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.6. Signal detection and other safety risk assessment
    • 5.6.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Pharmacovigilance and Drug Safety Software Market: End Use Estimates & Trend Analysis

  • 6.1. End use Segment Dashboard
  • 6.2. End use Market Share Movement Analysis, 2024 & 2033
  • 6.3. Market Size & Forecasts and Trend Analysis, by End Use, 2021 to 2033 (USD Million)
  • 6.4. Healthcare Companies (Pharmaceuticals & Biotechnology Companies)
    • 6.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5. CROs/BPOs or PV service providers when outsourced.
    • 6.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.6. Others
    • 6.6.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Pharmacovigilance and Drug Safety Software Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Market Dashboard
  • 7.2. Regional Market: Key Takeaways
  • 7.3. North America
    • 7.3.1. North America Pharmacovigilance and Drug Safety Software market estimates and forecasts, 2021 - 2033 (USD Million)
    • 7.3.2. U.S.
      • 7.3.2.1. Key country dynamic
      • 7.3.2.2. Regulatory framework
      • 7.3.2.3. Competitive insights
      • 7.3.2.4. U.S. Pharmacovigilance and Drug Safety Software market estimates and forecasts, 2021 - 2033 (USD Million)
    • 7.3.3. Canada
      • 7.3.3.1. Key country dynamic
      • 7.3.3.2. Regulatory framework
      • 7.3.3.3. Competitive insights
      • 7.3.3.4. Canada Pharmacovigilance and Drug Safety Software market estimates and forecasts, 2021 - 2033 (USD Million)
    • 7.3.4. Mexico
      • 7.3.4.1. Key country dynamic
      • 7.3.4.2. Regulatory framework
      • 7.3.4.3. Competitive insights
      • 7.3.4.4. Mexico Pharmacovigilance and Drug Safety Software market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.4. Europe
    • 7.4.1. Europe Pharmacovigilance and Drug Safety Software market estimates and forecasts, 2021 - 2033 (USD Million)
    • 7.4.2. Germany
      • 7.4.2.1. Key country dynamic
      • 7.4.2.2. Regulatory framework
      • 7.4.2.3. Competitive insights
      • 7.4.2.4. Germany Pharmacovigilance and Drug Safety Software market estimates and forecasts, 2021 - 2033 (USD Million)
    • 7.4.3. UK
      • 7.4.3.1. Key country dynamic
      • 7.4.3.2. Regulatory framework
      • 7.4.3.3. Competitive insights
      • 7.4.3.4. UK Pharmacovigilance and Drug Safety Software market estimates and forecasts, 2021 - 2033 (USD Million)
    • 7.4.4. France
      • 7.4.4.1. Key country dynamic
      • 7.4.4.2. Regulatory framework
      • 7.4.4.3. Competitive insights
      • 7.4.4.4. France Pharmacovigilance and Drug Safety Software market estimates and forecasts, 2021 - 2033 (USD Million)
    • 7.4.5. Italy
      • 7.4.5.1. Key country dynamic
      • 7.4.5.2. Regulatory framework
      • 7.4.5.3. Competitive insights
      • 7.4.5.4. Italy Pharmacovigilance and Drug Safety Software market estimates and forecasts, 2021 - 2033 (USD Million)
    • 7.4.6. Spain
      • 7.4.6.1. Key country dynamic
      • 7.4.6.2. Regulatory framework
      • 7.4.6.3. Competitive insights
      • 7.4.6.4. Spain Pharmacovigilance and Drug Safety Software market estimates and forecasts, 2021 - 2033 (USD Million)
    • 7.4.7. Denmark
      • 7.4.7.1. Key country dynamic
      • 7.4.7.2. Regulatory framework
      • 7.4.7.3. Competitive insights
      • 7.4.7.4. Denmark Pharmacovigilance and Drug Safety Software market estimates and forecasts, 2021 - 2033 (USD Million)
    • 7.4.8. Sweden
      • 7.4.8.1. Key country dynamic
      • 7.4.8.2. Regulatory framework
      • 7.4.8.3. Competitive insights
      • 7.4.8.4. Sweden Pharmacovigilance and Drug Safety Software market estimates and forecasts, 2021 - 2033 (USD Million)
    • 7.4.9. Norway
      • 7.4.9.1. Key country dynamic
      • 7.4.9.2. Regulatory framework
      • 7.4.9.3. Competitive insights
      • 7.4.9.4. Norway Pharmacovigilance and Drug Safety Software market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.5. Asia Pacific
    • 7.5.1. Asia Pacific Pharmacovigilance and Drug Safety Software market estimates and forecasts, 2021 - 2033 (USD Million)
    • 7.5.2. Japan
      • 7.5.2.1. Key country dynamic
      • 7.5.2.2. Regulatory framework
      • 7.5.2.3. Competitive insights
      • 7.5.2.4. Japan Pharmacovigilance and Drug Safety Software market estimates and forecasts, 2021 - 2033 (USD Million)
    • 7.5.3. China
      • 7.5.3.1. Key country dynamic
      • 7.5.3.2. Regulatory framework
      • 7.5.3.3. Competitive insights
      • 7.5.3.4. China Pharmacovigilance and Drug Safety Software market estimates and forecasts, 2021 - 2033 (USD Million)
    • 7.5.4. India
      • 7.5.4.1. Key country dynamic
      • 7.5.4.2. Regulatory framework
      • 7.5.4.3. Competitive insights
      • 7.5.4.4. India Pharmacovigilance and Drug Safety Software market estimates and forecasts, 2021 - 2033 (USD Million)
    • 7.5.5. South Korea
      • 7.5.5.1. Key country dynamic
      • 7.5.5.2. Regulatory framework
      • 7.5.5.3. Competitive insights
      • 7.5.5.4. South Korea Pharmacovigilance and Drug Safety Software market estimates and forecasts, 2021 - 2033 (USD Million)
    • 7.5.6. Australia
      • 7.5.6.1. Key country dynamic
      • 7.5.6.2. Regulatory framework
      • 7.5.6.3. Competitive insights
      • 7.5.6.4. Australia Pharmacovigilance and Drug Safety Software market estimates and forecasts, 2021 - 2033 (USD Million)
    • 7.5.7. Thailand
      • 7.5.7.1. Key country dynamic
      • 7.5.7.2. Regulatory framework
      • 7.5.7.3. Competitive insights
      • 7.5.7.4. Thailand Pharmacovigilance and Drug Safety Software market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.6. Latin America
    • 7.6.1. Latin America Pharmacovigilance and Drug Safety Software Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.2. Brazil
      • 7.6.2.1. Key country dynamic
      • 7.6.2.2. Regulatory framework
      • 7.6.2.3. Competitive insights
      • 7.6.2.4. Brazil Pharmacovigilance and Drug Safety Software market estimates and forecasts, 2021 - 2033 (USD Million)
    • 7.6.3. Argentina
      • 7.6.3.1. Key country dynamic
      • 7.6.3.2. Regulatory framework
      • 7.6.3.3. Competitive insights
      • 7.6.3.4. Argentina Pharmacovigilance and Drug Safety Software market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.7. MEA
    • 7.7.1. MEA Pharmacovigilance and Drug Safety Software market estimates and forecasts, 2021 - 2033 (USD Million)
    • 7.7.2. South Africa
      • 7.7.2.1. Key country dynamic
      • 7.7.2.2. Regulatory framework
      • 7.7.2.3. Competitive insights
      • 7.7.2.4. South Africa Pharmacovigilance and Drug Safety Software market estimates and forecasts, 2021 - 2033 (USD Million)
    • 7.7.3. Saudi Arabia
      • 7.7.3.1. Key country dynamic
      • 7.7.3.2. Regulatory framework
      • 7.7.3.3. Competitive insights
      • 7.7.3.4. Saudi Arabia Pharmacovigilance and Drug Safety Software market estimates and forecasts, 2021 - 2033 (USD Million)
    • 7.7.4. UAE
      • 7.7.4.1. Key country dynamic
      • 7.7.4.2. Regulatory framework
      • 7.7.4.3. Competitive insights
      • 7.7.4.4. UAE Pharmacovigilance and Drug Safety Software market estimates and forecasts, 2021 - 2033 (USD Million)
    • 7.7.5. Kuwait
      • 7.7.5.1. Key country dynamic
      • 7.7.5.2. Regulatory framework
      • 7.7.5.3. Competitive insights
      • 7.7.5.4. Kuwait Pharmacovigilance and Drug Safety Software market estimates and forecasts, 2021 - 2033 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Participant Overview
  • 8.2. Company Market Position Analysis/Company Market Share Analysis, (2024)
  • 8.3. Company Categorization
  • 8.4. Strategy Mapping
  • 8.5. Company Profiles/Listing
    • 8.5.1. Oracle (Cerner)
      • 8.5.1.1. Overview
      • 8.5.1.2. Financial performance
      • 8.5.1.3. Product benchmarking
      • 8.5.1.4. Strategic initiatives
    • 8.5.2. Accenture
      • 8.5.2.1. Overview
      • 8.5.2.2. Financial performance
      • 8.5.2.3. Product benchmarking
      • 8.5.2.4. Strategic initiatives
    • 8.5.3. IBM Corporation
      • 8.5.3.1. Overview
      • 8.5.3.2. Financial performance
      • 8.5.3.3. Product benchmarking
      • 8.5.3.4. Strategic initiatives
    • 8.5.4. ITClinical
      • 8.5.4.1. Overview
      • 8.5.4.2. Financial performance
      • 8.5.4.3. Product benchmarking
      • 8.5.4.4. Strategic initiatives
    • 8.5.5. UBC (United BioSource Corporation)
      • 8.5.5.1. Overview
      • 8.5.5.2. Financial performance
      • 8.5.5.3. Product benchmarking
      • 8.5.5.4. Strategic initiatives
    • 8.5.6. Ab Cube
      • 8.5.6.1. Overview
      • 8.5.6.2. Financial performance
      • 8.5.6.3. Product benchmarking
      • 8.5.6.4. Strategic initiatives
    • 8.5.7. Ennov
      • 8.5.7.1. Overview
      • 8.5.7.2. Financial performance
      • 8.5.7.3. Product benchmarking
      • 8.5.7.4. Strategic initiatives
    • 8.5.8. EXTEDO
      • 8.5.8.1. Overview
      • 8.5.8.2. Financial performance
      • 8.5.8.3. Product benchmarking
      • 8.5.8.4. Strategic initiatives
    • 8.5.9. Veeva Systems
      • 8.5.9.1. Overview
      • 8.5.9.2. Financial performance
      • 8.5.9.3. Product benchmarking
      • 8.5.9.4. Strategic initiatives
    • 8.5.10. IQVIA
      • 8.5.10.1. Overview
      • 8.5.10.2. Financial performance
      • 8.5.10.3. Product benchmarking
      • 8.5.10.4. Strategic initiatives
    • 8.5.11. Sarjen Systems Pvt. Ltd.
      • 8.5.11.1. Overview
      • 8.5.11.2. Financial performance
      • 8.5.11.3. Product benchmarking
      • 8.5.11.4. Strategic initiatives
    • 8.5.12. Flex Databases
      • 8.5.12.1. Overview
      • 8.5.12.2. Financial performance
      • 8.5.12.3. Product benchmarking
      • 8.5.12.4. Strategic initiatives
    • 8.5.13. Tepsivo Oy
      • 8.5.13.1. Overview
      • 8.5.13.2. Financial performance
      • 8.5.13.3. Product benchmarking
      • 8.5.13.4. Strategic initiatives
    • 8.5.14. ArisGlobal
      • 8.5.14.1. Overview
      • 8.5.14.2. Financial performance
      • 8.5.14.3. Product benchmarking
      • 8.5.14.4. Strategic initiatives
    • 8.5.15. EVERSANA
      • 8.5.15.1. Overview
      • 8.5.15.2. Financial performance
      • 8.5.15.3. Product benchmarking
      • 8.5.15.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviation
  • Table 2 List of secondary data sources
  • Table 3 North America Pharmacovigilance and Drug Safety Software market, by country, 2021 - 2033 (USD Million)
  • Table 4 North America Pharmacovigilance and Drug Safety Software market, by deployment, 2021 - 2033 (USD Million)
  • Table 5 North America Pharmacovigilance and Drug Safety Software market, by functionality, 2021 - 2033 (USD Million)
  • Table 6 North America Pharmacovigilance and Drug Safety Software market, by end use, 2021 - 2033 (USD Million)
  • Table 7 U.S. Pharmacovigilance and Drug Safety Software market, by deployment, 2021 - 2033 (USD Million)
  • Table 8 U.S. Pharmacovigilance and Drug Safety Software market, by functionality, 2021 - 2033 (USD Million)
  • Table 9 U.S. Pharmacovigilance and Drug Safety Software market, by end use, 2021 - 2033 (USD Million)
  • Table 10 Canada Pharmacovigilance and Drug Safety Software market, by deployment, 2021 - 2033 (USD Million)
  • Table 11 Canada Pharmacovigilance and Drug Safety Software market, by functionality, 2021 - 2033 (USD Million)
  • Table 12 Canada Pharmacovigilance and Drug Safety Software market, by end use, 2021 - 2033 (USD Million)
  • Table 13 Mexico Pharmacovigilance and Drug Safety Software market, by functionality, 2021 - 2033 (USD Million)
  • Table 14 Mexico Pharmacovigilance and Drug Safety Software market, by deployment, 2021 - 2033 (USD Million)
  • Table 15 Mexico Pharmacovigilance and Drug Safety Software market, by end use, 2021 - 2033 (USD Million)
  • Table 16 Europe Pharmacovigilance and Drug Safety Software market, by country, 2021 - 2033 (USD Million)
  • Table 17 Europe Pharmacovigilance and Drug Safety Software market, by deployment, 2021 - 2033 (USD Million)
  • Table 18 Europe Pharmacovigilance and Drug Safety Software market, by functionality, 2021 - 2033 (USD Million)
  • Table 19 Europe Pharmacovigilance and Drug Safety Software market, by end use, 2021 - 2033 (USD Million)
  • Table 20 Germany Pharmacovigilance and Drug Safety Software market, by deployment, 2021 - 2033 (USD Million)
  • Table 21 Germany Pharmacovigilance and Drug Safety Software market, by functionality, 2021 - 2033 (USD Million)
  • Table 22 Germany Pharmacovigilance and Drug Safety Software market, by end use, 2021 - 2033 (USD Million)
  • Table 23 U.K. Pharmacovigilance and Drug Safety Software market, by deployment, 2021 - 2033 (USD Million)
  • Table 24 U.K. Pharmacovigilance and Drug Safety Software market, by functionality, 2021 - 2033 (USD Million)
  • Table 25 U.K. Pharmacovigilance and Drug Safety Software market, by end use, 2021 - 2033 (USD Million)
  • Table 26 France Pharmacovigilance and Drug Safety Software market, by deployment, 2021 - 2033 (USD Million)
  • Table 27 France Pharmacovigilance and Drug Safety Software market, by functionality, 2021 - 2033 (USD Million)
  • Table 28 France Pharmacovigilance and Drug Safety Software market, by end use, 2021 - 2033 (USD Million)
  • Table 29 Italy Pharmacovigilance and Drug Safety Software market, by deployment, 2021 - 2033 (USD Million)
  • Table 30 Italy Pharmacovigilance and Drug Safety Software market, by functionality, 2021 - 2033 (USD Million)
  • Table 31 Italy Pharmacovigilance and Drug Safety Software market, by end use, 2021 - 2033 (USD Million)
  • Table 32 Spain Pharmacovigilance and Drug Safety Software market, by deployment, 2021 - 2033 (USD Million)
  • Table 33 Spain Pharmacovigilance and Drug Safety Software market, by functionality, 2021 - 2033 (USD Million)
  • Table 34 Spain Pharmacovigilance and Drug Safety Software market, by end use, 2021 - 2033 (USD Million)
  • Table 35 Sweden Pharmacovigilance and Drug Safety Software market, by deployment, 2021 - 2033 (USD Million)
  • Table 36 Sweden Pharmacovigilance and Drug Safety Software market, by functionality, 2021 - 2033 (USD Million)
  • Table 37 Sweden Pharmacovigilance and Drug Safety Software market, by end use, 2021 - 2033 (USD Million)
  • Table 38 Denmark Pharmacovigilance and Drug Safety Software market, by deployment, 2021 - 2033 (USD Million)
  • Table 39 Denmark Pharmacovigilance and Drug Safety Software market, by functionality, 2021 - 2033 (USD Million)
  • Table 40 Denmark Pharmacovigilance and Drug Safety Software market, by end use, 2021 - 2033 (USD Million)
  • Table 41 Norway Pharmacovigilance and Drug Safety Software market, by deployment, 2021 - 2033 (USD Million)
  • Table 42 Norway Pharmacovigilance and Drug Safety Software market, by functionality, 2021 - 2033 (USD Million)
  • Table 43 Norway Pharmacovigilance and Drug Safety Software market, by end use, 2021 - 2033 (USD Million)
  • Table 44 Asia Pacific Pharmacovigilance and Drug Safety Software market, by country, 2021 - 2033 (USD Million)
  • Table 45 Asia Pacific Pharmacovigilance and Drug Safety Software market, by deployment, 2021 - 2033 (USD Million)
  • Table 46 Asia Pacific Pharmacovigilance and Drug Safety Software market, by functionality, 2021 - 2033 (USD Million)
  • Table 47 Asia Pacific Pharmacovigilance and Drug Safety Software market, by end use, 2021 - 2033 (USD Million)
  • Table 48 China Pharmacovigilance and Drug Safety Software market, by deployment, 2021 - 2033 (USD Million)
  • Table 49 China Pharmacovigilance and Drug Safety Software market, by functionality, 2021 - 2033 (USD Million)
  • Table 50 China Pharmacovigilance and Drug Safety Software market, by end use, 2021 - 2033 (USD Million)
  • Table 51 Japan Pharmacovigilance and Drug Safety Software market, by deployment, 2021 - 2033 (USD Million)
  • Table 52 Japan Pharmacovigilance and Drug Safety Software market, by functionality, 2021 - 2033 (USD Million)
  • Table 53 Japan Pharmacovigilance and Drug Safety Software market, by end use, 2021 - 2033 (USD Million)
  • Table 54 India Pharmacovigilance and Drug Safety Software market, by deployment, 2021 - 2033 (USD Million)
  • Table 55 India Pharmacovigilance and Drug Safety Software market, by functionality, 2021 - 2033 (USD Million)
  • Table 56 India Pharmacovigilance and Drug Safety Software market, by end use, 2021 - 2033 (USD Million)
  • Table 57 Australia Pharmacovigilance and Drug Safety Software market, by deployment, 2021 - 2033 (USD Million)
  • Table 58 Austarila Pharmacovigilance and Drug Safety Software market, by functionality, 2021 - 2033 (USD Million)
  • Table 59 Australia Pharmacovigilance and Drug Safety Software market, by end use, 2021 - 2033 (USD Million)
  • Table 60 Thailand Pharmacovigilance and Drug Safety Software market, by deployment, 2021 - 2033 (USD Million)
  • Table 61 Thailand Pharmacovigilance and Drug Safety Software market, by functionality, 2021 - 2033 (USD Million)
  • Table 62 Thailand Pharmacovigilance and Drug Safety Software market, by end use, 2021 - 2033 (USD Million)
  • Table 63 South Korea Pharmacovigilance and Drug Safety Software market, by deployment, 2021 - 2033 (USD Million)
  • Table 64 South Korea Pharmacovigilance and Drug Safety Software market, by functionality, 2021 - 2033 (USD Million)
  • Table 65 South Korea Pharmacovigilance and Drug Safety Software market, by end use, 2021 - 2033 (USD Million)
  • Table 66 Latin America Pharmacovigilance and Drug Safety Software market, by country, 2021 - 2033 (USD Million)
  • Table 67 Latin America Pharmacovigilance and Drug Safety Software market, by deployment, 2021 - 2033 (USD Million)
  • Table 68 Latin America Pharmacovigilance and Drug Safety Software market, by functionality, 2021 - 2033 (USD Million)
  • Table 69 Latin America Pharmacovigilance and Drug Safety Software market, by end use, 2021 - 2033 (USD Million)
  • Table 70 Brazil Pharmacovigilance and Drug Safety Software market, by deployment, 2021 - 2033 (USD Million)
  • Table 71 Brazil Pharmacovigilance and Drug Safety Software market, by functionality, 2021 - 2033 (USD Million)
  • Table 72 Brazil Pharmacovigilance and Drug Safety Software market, by end use, 2021 - 2033 (USD Million)
  • Table 73 Argentina Pharmacovigilance and Drug Safety Software market, by deployment, 2021 - 2033 (USD Million)
  • Table 74 Argentina Pharmacovigilance and Drug Safety Software market, by functionality, 2021 - 2033 (USD Million)
  • Table 75 Argentina Pharmacovigilance and Drug Safety Software market, by end use, 2021 - 2033 (USD Million)
  • Table 76 MEA Pharmacovigilance and Drug Safety Software market, by country, 2021 - 2033 (USD Million)
  • Table 77 MEA Pharmacovigilance and Drug Safety Software market, by deployment, 2021 - 2033 (USD Million)
  • Table 78 MEA Pharmacovigilance and Drug Safety Software market, by functionality, 2021 - 2033 (USD Million)
  • Table 79 MEA Pharmacovigilance and Drug Safety Software market, by end use, 2021 - 2033 (USD Million)
  • Table 80 South Africa Pharmacovigilance and Drug Safety Software market, by deployment, 2021 - 2033 (USD Million)
  • Table 81 South Africa Pharmacovigilance and Drug Safety Software market, by functionality, 2021 - 2033 (USD Million)
  • Table 82 South Africa Pharmacovigilance and Drug Safety Software market, by end use, 2021 - 2033 (USD Million)
  • Table 83 Saudi Arabia Pharmacovigilance and Drug Safety Software market, by deployment, 2021 - 2033 (USD Million)
  • Table 84 Saudi Arabia Pharmacovigilance and Drug Safety Software market, by functionality, 2021 - 2033 (USD Million)
  • Table 85 Saudi Arabia Pharmacovigilance and Drug Safety Software market, by end use, 2021 - 2033 (USD Million)
  • Table 86 UAE Pharmacovigilance and Drug Safety Software market, by deployment, 2021 - 2033 (USD Million)
  • Table 87 UAE Pharmacovigilance and Drug Safety Software market, by functionality, 2021 - 2033 (USD Million)
  • Table 88 UAE Pharmacovigilance and Drug Safety Software market, by end use, 2021 - 2033 (USD Million)
  • Table 89 Kuwait Pharmacovigilance and Drug Safety Software market, by deployment, 2021 - 2033 (USD Million)
  • Table 90 Kuwait Pharmacovigilance and Drug Safety Software market, by functionality, 2021 - 2033 (USD Million)
  • Table 91 Kuwait Pharmacovigilance and Drug Safety Software market, by end use, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Market formulation & validation
  • Fig. 4 Pharmacovigilance and Drug Safety Software market: Market outlook
  • Fig. 5 Pharmacovigilance and Drug Safety Software market: Segment outlook
  • Fig. 6 Pharmacovigilance and Drug Safety Software market: Competitive landscape outlook
  • Fig. 7 Parent market outlook
  • Fig. 8 Pharmacovigilance and Drug Safety Software Market Driver Impact
  • Fig. 9 Pharmacovigilance and Drug Safety Software market Restraint impact
  • Fig. 10 Pharmacovigilance and Drug Safety Software market, deployment outlook key takeaways (USD Million)
  • Fig. 11 Pharmacovigilance and Drug Safety Software market: deployment movement analysis, (USD Million)
  • Fig. 12 On-Premise market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 13 On-demand market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 14 Pharmacovigilance and Drug Safety Software market, functionality outlook key takeaways (USD Million)
  • Fig. 15 Pharmacovigilance and Drug Safety Software market functionality movement analysis, (USD Million)
  • Fig. 16 Case data collection and management market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 17 Adverse event reporting and analysis market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 18 Signal detection and other safety risk assessment market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 19 Pharmacovigilance and Drug Safety Software market, end use outlook key takeaways (USD Million)
  • Fig. 20 Pharmacovigilance and Drug Safety Software market: end use movement analysis, (USD Million)
  • Fig. 21 Healthcare Companies (Pharmaceuticals & Biotechnology Companies) market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 22 CROs/BPOs or PV service providers when outsourced market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 23 Others market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 24 Regional marketplace: Key takeaways
  • Fig. 25 Pharmacovigilance and Drug Safety Software market: Regional outlook, 2024 & 2033
  • Fig. 26 North America Pharmacovigilance and Drug Safety Software market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 27 US Pharmacovigilance and Drug Safety Software market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 28 Canada Pharmacovigilance and Drug Safety Software market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 29 Mexico Pharmacovigilance and Drug Safety Software market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 30 Europe Pharmacovigilance and Drug Safety Software market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 31 UK Pharmacovigilance and Drug Safety Software market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 32 Germany Pharmacovigilance and Drug Safety Software market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 33 France Pharmacovigilance and Drug Safety Software market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 34 Italy Pharmacovigilance and Drug Safety Software market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 35 Spain Pharmacovigilance and Drug Safety Software market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 36 Denmark Pharmacovigilance and Drug Safety Software market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 37 Sweden Pharmacovigilance and Drug Safety Software market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 38 Norway Pharmacovigilance and Drug Safety Software market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 39 Asia Pacific Pharmacovigilance and Drug Safety Software market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 40 Japan Pharmacovigilance and Drug Safety Software market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 41 China Pharmacovigilance and Drug Safety Software market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 42 India Pharmacovigilance and Drug Safety Software market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 43 South Korea Pharmacovigilance and Drug Safety Software market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 44 Australia Pharmacovigilance and Drug Safety Software market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 45 Thailand Pharmacovigilance and Drug Safety Software market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 46 Latin America Pharmacovigilance and Drug Safety Software market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 47 Brazil Pharmacovigilance and Drug Safety Software market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 48 MEA Pharmacovigilance and Drug Safety Software market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 49 South Africa Pharmacovigilance and Drug Safety Software market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 50 Saudi Arabia Pharmacovigilance and Drug Safety Software market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 51 UAE Pharmacovigilance and Drug Safety Software market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 52 Kuwait Pharmacovigilance and Drug Safety Software market estimates and forecasts, 2021 - 2033 (USD Million)